AL1

HarbisonWalker International intends to invest in converting closed Fairfield, Alabama plant into advanced refractories manufacturing hub for southern U.S. steelmakers

Retrieved on: 
Friday, January 14, 2022
Carbon, City, Technology, Robotics, AL1, CEO, Solution, Mechanics, Leadership, Automation, Industry, Goal, Aluminium, Efficiency, National Economic Council (United Kingdom), Workforce, MSCI EAFE, Investment, Renewable energy, HWI

The location is ideal for delivering quality refractory products and high-value services to our customers' growing steel operations in the southern U.S.," said Carol Jackson, Chairman and CEO, HarbisonWalker International.

Key Points: 
  • The location is ideal for delivering quality refractory products and high-value services to our customers' growing steel operations in the southern U.S.," said Carol Jackson, Chairman and CEO, HarbisonWalker International.
  • "Fairfield is excited to welcome HarbisonWalker International to our city as a southern hub for its operations.
  • We look forward to a continued relationship to help this global company grow," said Mayor Eddie Penny, City of Fairfield.
  • The company anticipates hiring 50 highly trained technicians and staff in a team-based environment at the plant.

Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1 for Adult Acute Lymphoblastic Leukemia

Retrieved on: 
Thursday, April 16, 2020
AL1

The active IND allows initiation of the US sites in the companys first pivotal study, AUTO1-AL1.

Key Points: 
  • The active IND allows initiation of the US sites in the companys first pivotal study, AUTO1-AL1.
  • Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
  • AUTO1 has a fast target binding off-rate designed to minimize excessive activation and associated cytokine release, which may reduce toxicity.
  • AUTO1 is currently being evaluated in two Phase 1 studies, one in pediatric ALL and one in adult ALL.